<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580372</url>
  </required_header>
  <id_info>
    <org_study_id>01332</org_study_id>
    <nct_id>NCT00580372</nct_id>
  </id_info>
  <brief_title>UARK 89-001 Phase II Study of Intensive &quot;TOTAL THERAPY&quot; For Untreated or Minimally Treated Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Intensive &quot;TOTAL THERAPY&quot; for Untreated or Minimally Treated Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This experimental study evaluates the effects of a series of intensive drug regimens as&#xD;
      initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months&#xD;
      apart in support of high-dose Melphalan, followed by Interferon treatment indefinitely.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:&#xD;
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAD</intervention_name>
    <description>3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-Dose cyclophosphamide</intervention_name>
    <description>Approximately 5-6 weeks after VAD 2 or 3:&#xD;
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemopoietic stem cell procurement</intervention_name>
    <description>Collection target = 10 x 10^6 cells/kg</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDAP</intervention_name>
    <description>Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hemopoietic Stem Cell Transplant 1</intervention_name>
    <description>4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hemopoietic Stem Cell Transplant 2</intervention_name>
    <description>4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance</intervention_name>
    <description>3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously untreated patients with the diagnosis of multiple myeloma are eligible.&#xD;
             Similarly, patients who have not had more than one cycle of standard chemotherapy or&#xD;
             up to one month of interferon and/or glucocorticoids are eligible.&#xD;
&#xD;
          -  Patients must have objective evidence of, or be symptomatic from, complications due to&#xD;
             myeloma (e.g., bone pain from fractures, weakness from anemia). Asymptomatic patients&#xD;
             may be treated only if the diagnosis is confirmed and if there is evidence of&#xD;
             increasing tumor mass (e.g., rising myeloma protein and/or increasing lytic lesions).&#xD;
&#xD;
          -  Asymptomatic patients with idiopathic monoclonal peaks, localized plasmacytomas, or&#xD;
             indolent, asymptomatic myeloma are not eligible for this study. Any patient without&#xD;
             documented increasing disease and/or clearly symptomatic disease is not eligible.&#xD;
&#xD;
          -  Measurable, direct manifestations of myeloma must be present, such as monoclonal serum&#xD;
             or urine globulins. Plasma cell tumors must also be documented. Patients without&#xD;
             protein criteria are eligible if bone marrow has &gt; 30% plasmacytosis documented by&#xD;
             bilateral bone marrow aspirations and biopsies.&#xD;
&#xD;
          -  Patients with all stages of multiple myeloma (I, II, III) are eligible. Necessary&#xD;
             baseline studies must be obtained to determine the stage prior to registration.&#xD;
&#xD;
          -  Patients may have received local radiation to painful compression fractures or lytic&#xD;
             bone lesions, provided that adequate autologous bone marrow can still be harvested.&#xD;
             Patients presenting with clinical conditions requiring radiotherapy (e.g. spinal cord&#xD;
             compression) may proceed with concurrent local radiation and VAD. Should compression&#xD;
             fractures of known prestudy lytic lesions occur during later, more myelosuppressive&#xD;
             phases of induction therapy, radiotherapy should be completed first prior to&#xD;
             proceeding with high-dose cyclophosphamide, EDAP or melphalan.&#xD;
&#xD;
          -  Patients should be older than 15 years of age and may be up to 65 years old.&#xD;
&#xD;
          -  Pregnant females are excluded from study.&#xD;
&#xD;
          -  Eligibility criteria change with the progress through the different phases of the&#xD;
             induction program towards the two cycles of marrow-ablative therapy. These are&#xD;
             summarized in the eligibility checklist.&#xD;
&#xD;
          -  Briefly, prior to VAD, patients must have a normal cardiac ejection fraction of &gt; 50%&#xD;
             (on ECHO cardiography or MUGGA scan), and fairly normal liver function tests&#xD;
             (bilirubin &lt; 2 mg% and serum transaminase levels less than 2 x normal). Screening for&#xD;
             viral hepatitis should be negative for acute or chronic active hepatitis. Positive&#xD;
             antibody (anti-HAV, HBSAb) suggestive of remote exposure is acceptable. However,&#xD;
             patients who test positive for Hepatitis C antibody (anti-HCV) or HIV are ineligible.&#xD;
             Those with renal failure are eligible and should start VAD promptly and receive&#xD;
             additional medical measures as needed. Patients presenting with infections upon&#xD;
             presentation shall receive proper medical management prior to starting therapy.&#xD;
             Patient's performance status is not a criterion for entry on the VAD portion of this&#xD;
             program.&#xD;
&#xD;
          -  After 2 or 3 cycles of VAD, serum creatinine levels must be 2 mg% and carbon monoxide&#xD;
             diffusion capacity 50%. Cardiac and liver function requirements as with VAD.&#xD;
&#xD;
          -  Not until reaching the high-dose melphalan stage of 70 mg/M2 will there be a&#xD;
             requirement for Zubrod performance of 0 and 1 which must also be fulfilled with each&#xD;
             of the 2 marrow-ablative doses of melphalan (200 mg/M2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 10 x 108 cells/kg stored.&#xD;
&#xD;
          -  a granulocyte count of less than 1500/µl and a platelet count less than 150,000/µl.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Barlogie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences/MIRT</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>August 1, 2016</results_first_submitted>
  <results_first_submitted_qc>August 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.&#xD;
VAD: 3 Cycles (3rd cycle optional):&#xD;
Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20&#xD;
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:&#xD;
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1&#xD;
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg&#xD;
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.&#xD;
VAD: 3 Cycles (3rd cycle optional):&#xD;
Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20&#xD;
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:&#xD;
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1&#xD;
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg&#xD;
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" lower_limit="26.5" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</title>
        <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:&#xD;
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Treatment</title>
            <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.&#xD;
VAD: 3 Cycles (3rd cycle optional):&#xD;
Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20&#xD;
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:&#xD;
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1&#xD;
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg&#xD;
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy</title>
          <description>Relapse is defined by the unequivocal objective evidence of recurrent disease such as:&#xD;
myeloma-related cytogenetic abnormalities; bone marrow plasmacytosis &gt;10% or &gt;5% light chain restricted, non-diploid, plasma cells on clg/DNA; new skeletal or MRI lesions; hypercalcemia not explained by any other cause; or reappearance of M-protein in blood or urine not related to immune recovery, recent infection, and present for &gt;2 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment</title>
          <description>Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.&#xD;
VAD: 3 Cycles (3rd cycle optional):&#xD;
Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20&#xD;
High-Dose cyclophosphamide: Approximately 5-6 weeks after VAD 2 or 3:&#xD;
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1&#xD;
Hemopoietic stem cell procurement: Collection target = 10 x 10^6 cells/kg&#xD;
EDAP: Approximately 5-6 weeks after high-dose cyclophosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Anemia Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Neutropeni Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>WBC Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thrombocyt Grade 4</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 3</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 3</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 3</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 3</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 3</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory grade 3</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Metabolic/laboratory grade 4</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bicarbonat grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 3</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 3</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 4</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypermagne grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 3</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 4</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 3</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 3</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 4</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 3</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 4</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary grade 3</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary grade 4</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 3</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 4</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia grade 2</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Thrombocyt grade 2</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary/ pancreas grade 1</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hepatobiliary/pancreas grade 2</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 1</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Alkaline grade 2</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 1</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bilirubin grade 2</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 1</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoalbumi grade 2</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 1</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGOT (AST) grade 2</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 1</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) grade 2</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/laboratory grade 2</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bicarbonat grade 1</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypercalce grade 1</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 1</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperglyce grade 2</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyperkalem grade 2</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypemagne grade 1</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypematre grade 1</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypocalcem grade 2</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypokalemi grade 1</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 1</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypomagnes grade 2</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hyponatrem grade 1</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypophosph grade 2</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/genitourinary grade 1</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary grade 2</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 1</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Creatinine grade 2</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bart Barlogie</name_or_title>
      <organization>University of Arkansas for Medical Science</organization>
      <phone>501-526-2873</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

